Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Vegting Y, Reneman L, Booij J.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3473-501. doi: 10.1007/s00213-016-4396-5. Epub 2016 Aug 28. Review.

2.

Neurobiological signatures associated with alcohol and drug use in the human adolescent brain.

Silveri MM, Dager AD, Cohen-Gilbert JE, Sneider JT.

Neurosci Biobehav Rev. 2016 Nov;70:244-259. doi: 10.1016/j.neubiorev.2016.06.042. Epub 2016 Jul 1. Review.

PMID:
27377691
3.

Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective.

Kuypers KP, Theunissen EL, van Wel JH, de Sousa Fernandes Perna EB, Linssen A, Sambeth A, Schultz BG, Ramaekers JG.

PLoS One. 2016 Feb 23;11(2):e0149438. doi: 10.1371/journal.pone.0149438. eCollection 2016.

4.

3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Meyer JS.

Subst Abuse Rehabil. 2013 Nov 21;4:83-99. doi: 10.2147/SAR.S37258. eCollection 2013. Review.

5.

Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Di Iorio CR, Watkins TJ, Dietrich MS, Cao A, Blackford JU, Rogers B, Ansari MS, Baldwin RM, Li R, Kessler RM, Salomon RM, Benningfield M, Cowan RL.

Arch Gen Psychiatry. 2012 Apr;69(4):399-409. doi: 10.1001/archgenpsychiatry.2011.156. Epub 2011 Dec 5.

6.

Prospective memory deficits in Ecstasy users: effects of longer ongoing task delay interval.

Weinborn M, Woods SP, Nulsen C, Park K.

J Clin Exp Neuropsychol. 2011 Dec;33(10):1119-28. doi: 10.1080/13803395.2011.614595. Epub 2011 Nov 3.

7.

MDMA (Ecstasy) association with impaired fMRI BOLD thalamic coherence and functional connectivity.

Salomon RM, Karageorgiou J, Dietrich MS, McLellan JY, Charboneau EJ, Blackford JU, Cowan RL.

Drug Alcohol Depend. 2012 Jan 1;120(1-3):41-7. doi: 10.1016/j.drugalcdep.2011.06.022. Epub 2011 Jul 31.

8.

Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats.

Shen EY, Ali SF, Meyer JS.

Neuropharmacology. 2011 Dec;61(8):1183-92. doi: 10.1016/j.neuropharm.2011.07.002. Epub 2011 Jul 13.

9.

Human Ecstasy use is associated with increased cortical excitability: an fMRI study.

Bauernfeind AL, Dietrich MS, Blackford JU, Charboneau EJ, Lillevig JG, Cannistraci CJ, Woodward ND, Cao A, Watkins T, Di Iorio CR, Cascio C, Salomon RM, Cowan RL.

Neuropsychopharmacology. 2011 May;36(6):1127-41. doi: 10.1038/npp.2010.244. Epub 2011 Feb 16.

10.

Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study.

Tai YF, Hoshi R, Brignell CM, Cohen L, Brooks DJ, Curran HV, Piccini P.

Neuropsychopharmacology. 2011 Mar;36(4):735-43. doi: 10.1038/npp.2010.201. Epub 2010 Dec 15.

11.

Evidence of neurotoxicity of ecstasy: sustained effects on electroencephalographic activity in polydrug users.

Adamaszek M, Khaw AV, Buck U, Andresen B, Thomasius R.

PLoS One. 2010 Nov 23;5(11):e14097. doi: 10.1371/journal.pone.0014097.

12.

MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain.

Perrine SA, Ghoddoussi F, Michaels MS, Hyde EM, Kuhn DM, Galloway MP.

Neurotoxicology. 2010 Dec;31(6):654-61. doi: 10.1016/j.neuro.2010.08.005. Epub 2010 Aug 26.

13.

Preliminary evidence of motor impairment among polysubstance 3,4-methylenedioxymethamphetamine users with intact neuropsychological functioning.

Bousman CA, Cherner M, Emory KT, Barron D, Grebenstein P, Atkinson JH, Heaton RK, Grant I; HNRC Group.

J Int Neuropsychol Soc. 2010 Nov;16(6):1047-55. doi: 10.1017/S1355617710000846. Epub 2010 Aug 25.

14.

Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.

Licata SC, Renshaw PF.

Ann N Y Acad Sci. 2010 Feb;1187:148-71. doi: 10.1111/j.1749-6632.2009.05143.x. Review.

15.

Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users.

Parrott AC.

Neuropsychobiology. 2009;60(3-4):148-58. doi: 10.1159/000253551. Epub 2009 Nov 5. Review.

16.

The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions.

Wu LT, Parrott AC, Ringwalt CL, Yang C, Blazer DG.

Am J Addict. 2009 Nov-Dec;18(6):452-61. doi: 10.3109/10550490903206049.

17.

MDMA (ecstasy) use is associated with reduced BOLD signal change during semantic recognition in abstinent human polydrug users: a preliminary fMRI study.

Raj V, Liang HC, Woodward ND, Bauernfeind AL, Lee J, Dietrich MS, Park S, Cowan RL.

J Psychopharmacol. 2010 Feb;24(2):187-201. doi: 10.1177/0269881109103203. Epub 2009 Mar 20.

18.

Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study.

Karageorgiou J, Dietrich MS, Charboneau EJ, Woodward ND, Blackford JU, Salomon RM, Cowan RL.

Neuroimage. 2009 Jul 1;46(3):817-26. doi: 10.1016/j.neuroimage.2009.02.029. Epub 2009 Mar 2.

19.
20.

Neuroimaging in human MDMA (Ecstasy) users.

Cowan RL, Roberts DM, Joers JM.

Ann N Y Acad Sci. 2008 Oct;1139:291-8. doi: 10.1196/annals.1432.007.

Supplemental Content

Support Center